title: DBA/2 mouse as an animal model for anti-influenza drug efficacy evaluation.
abstract: Influenza viruses are seasonally recurring human pathogens. Vaccines and antiviral drugs are available for influenza. However, the viruses, which often change themselves via antigenic drift and shift, demand constant efforts to update vaccine antigens every year and develop new agents with broad-spectrum antiviral efficacy. An animal model is critical for such efforts. While most human influenza viruses are unable to kill BALB/c mice, some strains have been shown to kill DBA/2 mice without prior adaptation. Therefore, in this study, we explored the feasibility of employing DBA/2 mice as a model in the development of anti-influenza drugs. Unlike the BALB/c strain, DBA/2 mice were highly susceptible and could be killed with a relatively low titer (50% DBA/2 lethal dose = 10(2.83) plaque-forming units) of the A/Korea/01/2009 virus (2009 pandemic H1N1 virus). When treated with a neuraminidase inhibitor, oseltamivir phosphate, infected DBA/2 mice survived until 14 days post-infection. The reduced morbidity of the infected DBA/2 mice was also consistent with the oseltamivir treatment. Taking these data into consideration, we propose that the DBA/2 mouse is an excellent animal model to evaluate antiviral efficacy against influenza infection and can be further utilized for combination therapies or bioactivity models of existing and newly developed anti-influenza drugs.
authors.affiliation: Department of Microbiology, Center for Medical Science Research, College of Medicine, Hallym University, Chuncheon, 200-702, Republic of Korea.
authors.forename: Jin Il
authors.initials: JI
authors.lastname: Kim
authors.forename: Sehee
authors.initials: S
authors.lastname: Park
authors.forename: Sangmoo
authors.initials: S
authors.lastname: Lee
authors.forename: Ilseob
authors.initials: I
authors.lastname: Lee
authors.forename: Jun
authors.initials: J
authors.lastname: Heo
authors.forename: Min-Woong
authors.initials: MW
authors.lastname: Hwang
authors.forename: Joon-Yong
authors.initials: JY
authors.lastname: Bae
authors.forename: Donghwan
authors.initials: D
authors.lastname: Kim
authors.forename: Seok-Il
authors.initials: SI
authors.lastname: Jang
authors.forename: Mee Sook
authors.initials: MS
authors.lastname: Park
authors.forename: Man-Seong
authors.initials: MS
authors.lastname: Park
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000008:administration & dosage*; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D005260:Female; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype / Q000187:drug effects* / Q000472:pathogenicity; D007251:Influenza, Human / Q000188:drug therapy* / Q000821:virology*; D051379:Mice; D008807:Mice, Inbred BALB C; D008811:Mice, Inbred DBA / Q000821:virology; D056910:Republic of Korea; D014774:Virulence / Q000187:drug effects
chemical_list: D000998:Antiviral Agents